Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Oxidation hypothesis of atherogenesis: HDL inflammatory index and apolipoprotein A-I mimetic peptides.

Yu R, Navab M.

Future Cardiol. 2007 May;3(3):309-19. doi: 10.2217/14796678.3.3.309.

PMID:
19804222
2.

Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management.

Shah PK, Chyu KY.

Trends Cardiovasc Med. 2005 Nov;15(8):291-6. Review.

PMID:
16297766
3.

Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease.

Navab KD, Elboudwarej O, Gharif M, Yu J, Hama SY, Safarpour S, Hough GP, Vakili L, Reddy ST, Navab M, Vaziri ND.

Curr Pharm Des. 2011;17(1):17-20. Review.

PMID:
21222643
4.

Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.

Sherman CB, Peterson SJ, Frishman WH.

Cardiol Rev. 2010 May-Jun;18(3):141-7. doi: 10.1097/CRD.0b013e3181c4b508. Review.

PMID:
20395699
5.

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM.

J Lipid Res. 2004 Jun;45(6):993-1007. Epub 2004 Apr 1. Review.

6.

Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.

Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM.

Curr Opin Lipidol. 2004 Dec;15(6):645-9. Review.

PMID:
15529023
7.

Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes.

Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, Ferrannini E, Reddy ST.

Diabetes. 2011 Oct;60(10):2617-23. doi: 10.2337/db11-0378. Epub 2011 Aug 18.

8.

Atherosclerotic risk factors in cardiovascular disease.

LaRosa JC.

J Reprod Med. 1986 Sep;31(9 Suppl):906-12.

PMID:
3772910
9.

Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins?

Vuilleumier N, Dayer JM, von Eckardstein A, Roux-Lombard P.

Swiss Med Wkly. 2013 May 25;143:w13781. doi: 10.4414/smw.2013.13781. Review.

11.

The promise of apolipoprotein A-I mimetics.

Mendez AJ.

Curr Opin Endocrinol Diabetes Obes. 2010 Apr;17(2):171-6. doi: 10.1097/MED.0b013e3283373cb5. Review.

PMID:
20125002
12.
13.
14.

High-density lipoproteins, inflammation and oxidative stress.

Tabet F, Rye KA.

Clin Sci (Lond). 2009 Jan;116(2):87-98. doi: 10.1042/CS20080106. Review.

PMID:
19076062
15.

Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.

Meyers CD, Kashyap ML.

Curr Opin Cardiol. 2005 Jul;20(4):307-12. Review.

PMID:
15956828
16.

The anti inflammatory effects of high density lipoproteins.

Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ.

Curr Med Chem. 2009;16(6):667-75. Review.

PMID:
19199930
17.
18.

Focus on high-density lipoproteins in reducing cardiovascular risk.

Brewer HB Jr.

Am Heart J. 2004 Jul;148(1 Suppl):S14-8.

PMID:
15211328
19.

[Lipid peroxidation--the factor promoting cholesterol accumulation in cells in atherogenesis].

Panasenko OM, Vol'nova TV, Azizova OA, Vladimirov IuA.

Biull Eksp Biol Med. 1988 Sep;106(9):277-80. Russian.

PMID:
3167175
20.

The double jeopardy of HDL.

Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman AM.

Ann Med. 2005;37(3):173-8. Review.

PMID:
16019715

Supplemental Content

Support Center